
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Holdings Inc. has demonstrated significant valuation potential through the Garda transaction, which offers substantial premiums to its stock prices and underscores the company's long-term market prospects. The strategic sale of non-Rolvedon assets to Cosette Pharmaceuticals indicates a focused operational approach and a commitment to enhancing its core offerings in oncology. Additionally, the reverse stock split mitigates delisting risks from NASDAQ, positioning Assertio more favorably in the marketplace and contributing to a more stable financial outlook.
Bears say
The analysis indicates a negative outlook for Assertio Holdings Inc., primarily due to several key risks that threaten its market position. Factors such as the inability to secure additional market share for ROLVEDON and Sympazan, high competition levels, and the potential loss of exclusivity for existing products contribute to these concerns. Additionally, the company faces significant financial strain highlighted by a substantial impairment of intangible assets and the presence of legacy products that have already lost market exclusivity, further undermining growth prospects.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares